User:Raia Hasan/Sandbox 1
From Proteopedia
(Difference between revisions)
| Line 13: | Line 13: | ||
'''Types of Botulinum Neurotoxins''' | '''Types of Botulinum Neurotoxins''' | ||
| - | Botulinum Neurotoxins A<ref name=A>Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]</ref> is the first type of toxin to be introduced into the cosmetic world with the abbreviated name, Botox. Botox is mainly used for treating facial imperfections, muscle spasms, and other conditions like chronic migraines, dystonia, blepharospasms, diabetic neuropathy, spinal cord injury, epicondylitis incontinence, hyperhidrosis, and many more. | + | Botulinum Neurotoxins A<ref name=A>Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]</ref> <ref name=mono>Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria</ref>is the first type of toxin to be introduced into the cosmetic world with the abbreviated name, Botox. Botox is mainly used for treating facial imperfections, muscle spasms, and other conditions like chronic migraines, dystonia, blepharospasms, diabetic neuropathy, spinal cord injury, epicondylitis incontinence, hyperhidrosis, and many more. |
The mechanism of action for type A: Consists of a heavy chain (100 kDa) and light chain (50 kDa) which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. <ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> | The mechanism of action for type A: Consists of a heavy chain (100 kDa) and light chain (50 kDa) which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. <ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> | ||
| Line 82: | Line 82: | ||
<ref name=sia>Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594</ref> | <ref name=sia>Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594</ref> | ||
<ref name=D>Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015</ref> | <ref name=D>Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015</ref> | ||
| - | <ref name= | + | <ref name=mono>Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria</ref> |
<ref name=zinc>Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200</ref> | <ref name=zinc>Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200</ref> | ||
<ref name=domains>Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902.</ref> | <ref name=domains>Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902.</ref> | ||
Revision as of 18:24, 2 May 2022
Botulinum Neurotoxin
| |||||||||||
References
- ↑ Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022
- ↑ Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]
- ↑ Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria
- ↑ Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0
- ↑ Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015
- ↑ 6.0 6.1 6.2 6.3 World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism
- ↑ Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123
- ↑ Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594
- ↑ How botox® is injected. The Cosmetic Skin Clinic. (2021, November 2). Retrieved April 27, 2022, from https://www.cosmeticskinclinic.com/advice-centre/how-botox-is-injected
- ↑ Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200
- ↑ Lacy DB, Tepp W, Cohen AC, DasGupta BR, Stevens RC. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998 Oct;5(10):898-902.
